{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:43:38Z","timestamp":1773243818146,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jinf.2013.07.015","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T12:02:05Z","timestamp":1373284925000},"page":"424-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis"],"prefix":"10.1016","volume":"67","author":[{"given":"April C.","family":"Pettit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bethel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Hirsch-Moverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Colson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","article-title":"Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999\u20132000","volume":"177","author":"Bennett","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jinf.2013.07.015_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa012972","article-title":"Changes in the transmission of tuberculosis in New York City from 1990 to 1999","volume":"346","author":"Geng","year":"2002","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jinf.2013.07.015_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJM199406163302402","article-title":"The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods","volume":"330","author":"Small","year":"1994","journal-title":"N Engl J Med"},{"issue":"RR-6","key":"10.1016\/j.jinf.2013.07.015_bib4","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"issue":"20","key":"10.1016\/j.jinf.2013.07.015_bib5","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"issue":"12 Suppl. 3","key":"10.1016\/j.jinf.2013.07.015_bib6","first-page":"S384","article-title":"Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999","volume":"7","author":"Jereb","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jinf.2013.07.015_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.jinf.2013.07.015_bib9","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.jinf.2013.07.015_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.jinf.2013.07.015_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-associated hepatitis. Report of an outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.jinf.2013.07.015_bib13","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fernandez-Villar","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2013.07.015_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1572-0241.2002.05704.x","article-title":"Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States","volume":"97","author":"Patel","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jinf.2013.07.015_bib16","first-page":"151","article-title":"Isoniazid hepatitis among pregnant and postpartum Hispanic patients","volume":"104","author":"Franks","year":"1989","journal-title":"Public Health Rep"},{"issue":"8","key":"10.1016\/j.jinf.2013.07.015_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"2 Pt 1","key":"10.1016\/j.jinf.2013.07.015_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"Snider","year":"1980","journal-title":"Tubercle"},{"issue":"6","key":"10.1016\/j.jinf.2013.07.015_bib20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1164\/ajrccm.158.6.9804029","article-title":"Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons","volume":"158","author":"Chin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jinf.2013.07.015_bib21","first-page":"31","article-title":"Tuberculosis infection and disease among persons seeking social services in New York City","volume":"1","author":"Schluger","year":"1997","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jama.1992.03490040080029","article-title":"High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy","volume":"268","author":"Selwyn","year":"1992","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib23","first-page":"1296","article-title":"Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons","volume":"127","author":"Lobato","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1086\/314037","article-title":"Treatment of latent tuberculosis infection in patients aged > or\u00a0=35 years","volume":"31","author":"Gilroy","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2013.07.015_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1164\/rccm.200510-1563OC","article-title":"The scope and impact of treatment of latent tuberculosis infection in the United States and Canada","volume":"173","author":"Sterling","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5588\/ijtld.12.0697","article-title":"Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada","volume":"17","author":"Colson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.jinf.2013.07.015_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jinf.2013.07.015_bib28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib29","first-page":"256","article-title":"Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity","volume":"4","author":"Ohno","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.jinf.2013.07.015_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2125.2000.00130.x","article-title":"The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects","volume":"49","author":"Welfare","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.jinf.2013.07.015_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/carcin\/18.7.1351","article-title":"Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England","volume":"18","author":"Welfare","year":"1997","journal-title":"Carcinogenesis"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445313001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445313001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:18:43Z","timestamp":1759007923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445313001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0163445313001977"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2013.07.015","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2013.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}